| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.2 |
| Profit before tax | -2.6 | 16.0 |
| Net income | -2.7 | 16.0 |
| EPS (diluted, $ a share) | $-0.48 | $2.84 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RLYB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rallybio Corp: key numbers
- Share price
- $15.43Close, Nov 16
- Market cap
- $83M
- Shares outstanding
- 5.38MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rallybio Corp
All →Rallybio M&A Deal with Avenzo Therapeutics, Inc.
Rallybio Corp announced that its pending merger with Avenzo Therapeutics is expected to close following the close of trading on November 20, 2026. The company also provided a timeline update for its previously announced special cash distribution of $13.90 per share, which will be paid to stockholders of record as of November 5, 2026, following Nasdaq due bill procedures.
- Counterparty
- Avenzo Therapeutics, Inc.
Rallybio Reverse Stock Split
Rallybio announced a 1-for-2 reverse stock split effective November 20, 2026, reducing outstanding shares from 5.6 million to 2.8 million. The split is being executed in connection with its pending merger with Avenzo Therapeutics, Inc., after which the combined company will trade under the symbol AVZO. The final ratio was mutually determined by both companies following shareholder approval at the November 4, 2026, annual meeting.
- Counterparty
- Avenzo Therapeutics, Inc.
Rallybio M&A Deal with Avenzo Therapeutics, Inc.
Rallybio Corporation has postponed the closing of its previously announced merger with Avenzo Therapeutics, Inc., which was originally expected to close on November 6, 2026. The delay is due to unsatisfied conditions related to the listing of the company's shares following the transaction. Consequently, the company has also delayed the funding and payment of its previously announced cash distribution to shareholders.
- Counterparty
- Avenzo Therapeutics, Inc.
Rallybio Shareholder Meeting
Rallybio Corporation held its 2026 Annual Meeting of Stockholders where shareholders approved the 2026 Equity Incentive Plan. The plan, which becomes effective upon the completion of the company's merger with Avenzo Therapeutics, initially reserves 18% of the combined company's outstanding common stock for issuance to employees and directors.
Rallybio Signs $82.7M M&A Deal with Avenzo Therapeutics, Inc.
Rallybio Corporation provided a status update on its pending merger with Avenzo Therapeutics, declaring a special cash distribution of approximately $82.7 million ($13.56 per share) to stockholders. The distribution is based on the company's estimated net cash exceeding zero prior to the merger closing and is scheduled for payment on November 13, 2026.
- Value
- $82.7M
- Counterparty
- Avenzo Therapeutics, Inc.